recentpopularlog in

#$#pharma

Goldman Sachs questions whether curing patients is a sustainable business model (arstechnica.com)
One-shot cures for diseases are not great for business—more specifically, they’re bad for longterm profits—Goldman Sachs analysts noted in an April 10 report for biotech clients, first reported by CNBC. The investment banks’ report, titled “The Genome Revolution,” asks clients the touchy question: “Is curing patients a sustainable business model?” The answer may be “no,” according to follow-up information provided. Analyst Salveen Richter and colleagues laid it out: The potential to deliver “one shot cures” is one of the most attractive aspects of gene therapy, genetically engineered cell therapy, and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies... While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.


in the both-totally-logical-and-utterly-depressing category

to be fair, i guess economists would say that one-shot cures have massive positive externalities, which, well are not reaped directly by pharma. sad!
%econ  #$#pharma  #$#innov  %contrarian 
10 days ago by lemeb

Copy this bookmark:





to read